Breaking News Instant updates and real-time market news.

FGEN

FibroGen

$51.95

1.45 (2.87%)

, AUPH

Aurinia Pharmaceuticals

$6.26

0.15 (2.46%)

04:55
09/28/17
09/28
04:55
09/28/17
04:55

Leerink to hold a roundtable

RARE Disease & Immuno-Oncology Roundtable is being held in New York on September 27-28.

FGEN

FibroGen

$51.95

1.45 (2.87%)

AUPH

Aurinia Pharmaceuticals

$6.26

0.15 (2.46%)

EPZM

Epizyme

$17.25

0.85 (5.18%)

SELB

Selecta Biosciences

$19.38

0.72 (3.86%)

ALXN

Alexion

$139.45

-0.25 (-0.18%)

INSM

Insmed

$29.58

1.47 (5.23%)

DOVA

Dova Pharmaceuticals

$24.47

0.4 (1.66%)

EARS

Auris Medical

$0.73

-0.0004 (-0.05%)

ACHN

Achillion

$4.37

0.3 (7.37%)

CDTX

Cidara Therapeutics

$7.95

-0.1 (-1.24%)

VRTX

Vertex

$149.07

0.61 (0.41%)

BOLD

Audentes Therapeutics

$29.97

0.5 (1.70%)

WVE

Wave Life Sciences

$23.25

1.5 (6.90%)

EDGE

Edge Therapeutics

$10.61

0.76 (7.72%)

PRQR

ProQR Therapeutics

$5.15

-0.05 (-0.96%)

CBAY

CymaBay

$8.03

0.33 (4.29%)

QURE

uniQure

$8.78

-0.02 (-0.23%)

SCMP

Sucampo

$11.70

-0.05 (-0.43%)

  • 02

    Oct

  • 04

    Oct

  • 05

    Oct

  • 11

    Oct

  • 23

    Oct

FGEN FibroGen
$51.95

1.45 (2.87%)

08/08/17
LEER
08/08/17
NO CHANGE
Target $82
LEER
Outperform
FibroGen price target raised to $82 from $52 at Leerink
Leerink analyst Geoffrey Porges raised his price target for FibroGen to $82 from $52 after the company reported Q2 results and disclosed positive top-line results for the first phase of the ongoing phase II trial of pamrevlumab in idiopathic pulmonary fibrosis. The analyst reiterates an Outperform rating on the shares.
08/08/17
STFL
08/08/17
NO CHANGE
STFL
FibroGen price target raised to $80 from $38 at Stifel
Stifel analyst Thmas Shrader raised his price target on FibroGen after the company announced statistically significant trial results for its Pamrevlumab drug in IPF. The analyst estimates that the drug has a 50% chance of succeeding in IPF. He raised his price target on the shares to $80 from $38 and keeps a Buy rating on the stock.
08/08/17
SBSH
08/08/17
NO CHANGE
Target $65
SBSH
Buy
FibroGen price target raised to $65 from $48 at Citi
Citi analyst Joel Beatty raised his price target for FibroGen to $65 after the company's Phase 2 trial of Pamrevlumab in idiopathic pulmonary fibrosis met its primary endpoint. The monotherapy benefit appears comparable to the two approved IPF drugs, which is encouraging, Beatty tells investors in a research note. He increased his probability of success for Pamrevlumab in IPF to 65% from 20%. FibroGen continues to be the analyst's top pick.
08/14/17
JEFF
08/14/17
NO CHANGE
JEFF
Buy
Expert IPF call positive for FibroGen, says Jefferies
Jefferies analyst Michael Yee says his call with two idiopathic pulmonary fibrosis experts was net positive for FibroGen (FGEN). Based on the available data, the experts estimated a 30%-40%-plus probability of success in Phase 3 for the company. The experts were "more conservative in the interpretation" of the data reported by Galapagos NV (GLPG), Yee tells investors in a research note. He reiterates a Buy rating on FibroGen given the "underappreciated value" for FG-3019 in IPF.
AUPH Aurinia Pharmaceuticals
$6.26

0.15 (2.46%)

03/06/17
FBRC
03/06/17
NO CHANGE
FBRC
FBR sees 'prime' merger environment for biotechs under Trump
Potential tax reform and FDA policy changes under President Trump could "prime the pump" for acquisitions of clinical-stage biotech companies by Big Pharma, FBR Capital analysts led by Chris Meekins tell investors in a research note. These police moves, coupled with the repeal of some taxes associated with the Affordable Care Act, are likely to increase funds for companies looking to make acquisitions, the analysts contend. Within its coverage universe, FBR sees TESARO (TSRO), Agile Therapeutics (AGRX), Kite Pharma (KITE), Juno Therapeutics (JUNO), Acceleron Pharma (XLRN), Abeona Therapeutics (ABEO), Aurinia Pharmaceuticals (AUPH), Geron (GERN) and Genocea Biosciences (GNCA) as "primary targets for those looking to make acquisitions."
04/10/17
CANT
04/10/17
INITIATION
Target $14
CANT
Overweight
Aurinia Pharmaceuticals initiated with an Overweight at Cantor
Cantor initiated Aurinia Pharmaceuticals with an Overweight and a $14 price target.
03/03/17
HCWC
03/03/17
NO CHANGE
Target $12
HCWC
Buy
Aurinia Pharmaceuticals price target raised to $12 from $8 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target on Aurinia Pharmaceuticals to $12 from $8 after the company reported that treatment of lupus nephritis with voclosporin demonstrated a substantial further improvement at 48 weeks. Given this type of "rare" treatment effect change over time, Arce said his conviction has increased that voclosporin can quickly emerge as the new standard-of-care in lupus nephritis treatment and he keeps a Buy rating on Aurinia shares.
09/13/17
ADAM
09/13/17
DOWNGRADE
Target $10
ADAM
Speculative Buy
Aurinia Pharmaceuticals downgraded to Speculative Buy from Buy at Canaccord
Canaccord analyst Neil Maruoka assumed coverage of Aurinia Pharmaceuticals and downgraded the stock to Speculative Buy from Buy, citing the high risks associated with biotech drug development. However, he believes the ongoing Phase III AURORA study has a good chance of success and sees Aurinia as undervalued based on the strength of data generated by voclosporin to date. Maruoka set a $10 price target on Aurinia shares.
EPZM Epizyme
$17.25

0.85 (5.18%)

09/20/17
09/20/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Biogen (BIIB) initiated with a Buy at SunTrust. 2. CymaBay (CBAY) initiated with an Overweight at Cantor. 3. Evolent Health (EVH) initiated with an Overweight at KeyBanc. 4. Epizyme (EPZM) initiated with a Buy at Jefferies. 5. Intuit (INTU) initiated with a Buy at Argus. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/15/17
RHCO
06/15/17
NO CHANGE
Target $21
RHCO
Buy
SunTrust ups odds of success for Epizyme's tazemetostat in follicular lymphoma
Following data presented at a lymphoma conference and the associated call held by Epizyme management, SunTrust analyst Peter Lawson increased his view of the probability of success and penetration for tazemetostat in follicular lymphoma patients with EZH2 mutations. The analyst, who adds that tazemetostat's favorable side effect profile bodes well for its potential use in a maintenance setting, keeps a Buy rating and $21 price target on Epizyme shares.
06/15/17
SBSH
06/15/17
NO CHANGE
Target $22
SBSH
Buy
Citi sees accelerated approval for Epizyme, ups price target
Epizyme's data yesterday for tazemetostat showed a "strong response" in follicular lymphoma patients with the EZH2 mutation and activity in other indications, Citi analyst Robyn Karnauskas tells investors in a research note. She believes the data support accelerated approval and raised her price target for the shares to $22 from $20. The analyst keeps a Buy rating on Epizyme.
09/20/17
JEFF
09/20/17
INITIATION
Target $23
JEFF
Buy
Epizyme initiated with a Buy at Jefferies
Jefferies analyst Carmen Augustine started Epizyme with a Buy rating and $23 price target. The company, with potential to have a drug on market as soon as 2019, has a a "catalyst-rich" next 12 months, the analyst contends. Augustine believes data are encouraging for tazemetostat in larger blood cancer indications.
SELB Selecta Biosciences
$19.38

0.72 (3.86%)

12/08/16
STFL
12/08/16
NO CHANGE
STFL
Selecta Biosciences price target raised to $32 from $23 at Stifel
Stifel analyst Thomas Shrader raised his price target on Selecta, saying that data on the company's SEL-212 treatment showed "initial proof of concept in humans with an acceptable safety profile for more serious disease states." He keeps a Buy rating on the shares.
ALXN Alexion
$139.45

-0.25 (-0.18%)

09/25/17
LEER
09/25/17
NO CHANGE
Target $182
LEER
Outperform
Alexion Soliris to continue dominance through 2020, says Leerink
Leerink analyst Geoffrey Porges notes that Alexion's Soliris was the first complement inhibitor to be approved by the FDA or EMA and has remained the only terminal complement inhibitor on the market. While some competitors have advanced to pivotal trials, and have established safety and efficacy, none have shown themselves to be superior to Soliris in efficacy, nor more convenient than ALXN1210, he adds. The analyst believes the development timelines for these new entrants suggest that Soliris will continue its dominance of the category through 2020, and even then will face its biggest challenge from Alexion's own next generation complement inhibitor, ALXN1210. Porges reiterates an Outperform rating and $182 price target on the shares.
09/14/17
RBCM
09/14/17
INITIATION
Target $161
RBCM
Outperform
Alexion initiated with an Outperform at RBC Capital
RBC Capital analyst Kennen MacKay initiated Alexion with an Outperform and a $161 price target saying shares are undervalued following management changes and restructuring. He said Soliris market dynamics suggest continued future growth despite PNH Patient competition.
09/14/17
LEER
09/14/17
NO CHANGE
Target $182
LEER
Outperform
Long-term follow-up confirms Alexion Soliris benefit, says Leerink
Leerink analyst Geoffrey Porges notes that Alexion announced the presentation of additional results from the open-label extension of the pivotal phase III REGAIN study of Soliris in refractory generalized myasthenia gravis. The analyst believes this longer-term follow-up analysis is highly supportive of the upcoming PDUFA on October 23. Porges reiterates an Outperform rating and $182 price target on the shares.
09/13/17
LEER
09/13/17
NO CHANGE
Target $182
LEER
Outperform
Alexion price target raised to $182 from $170 at Leerink
Leerink analyst Geoffrey Porges raised his price target for Alexion to $182 from $170 on valuation. The analyst reiterates an Outperform rating on the shares.
INSM Insmed
$29.58

1.47 (5.23%)

09/06/17
BARD
09/06/17
NO CHANGE
Target $32
BARD
Outperform
Insmed price target raised to $32 from $23 at Baird
Baird analyst Brian Skorney raised his price target on Insmed to $32 from $23 following the results of its long-awaited Phase 3 CONVERT data. The analyst noted its primary endpoints were better than expected. The secondary endpoints were not as positive, but he does not believe that will affect its approvability. Skorney reiterated his Outperform rating on Insmed shares.
09/05/17
COWN
09/05/17
NO CHANGE
Target $54
COWN
Outperform
Insmed 'strong' efficacy, safety data will drive approvals, says Cowen
Cowen analyst Ritu Baral noted that Insmed reported "strong" efficacy and safety data for ALIS, which she thinks will drive approval of the drug in the U.S., EU and Japan. Given the increased probability of success, she set a $54 price target on Insmed shares, which have more than doubled to $26.37 in early afternoon trading.
09/05/17
EVER
09/05/17
NO CHANGE
Target $40
EVER
Insmed price target raised to $40 from $28 at Evercore ISI
09/05/17
LEER
09/05/17
NO CHANGE
Target $36
LEER
Outperform
Insmed price target raised to $36 from $27 at Leerink
Leerink analyst Joseph Schwartz raised his price target for Insmed shares to $36 citing this morning's "better-than-expected" top-line results from the company's Phase 3 study for Alis in nontuberculous mycobacterium lung disease. The stock in midday trading is up 106%, or $13.06, to $25.35. The analyst continues to project a U.S. market launch in 2019 and now estimates peak revenue of $1.6B by 2031. Label expansion opportunities and earlier regulatory approvals may present further upside, Schwartz tells investors in a research note. He reiterates an Outperform rating on Insmed.
DOVA Dova Pharmaceuticals
$24.47

0.4 (1.66%)

08/31/17
RAJA
08/31/17
NO CHANGE
RAJA
Market Perform
Investors wrong to think Fosun will acquire Impax, says Raymond James
Raymond James analyst Elliot Wilbur says shares of Impax Laboratories (IPXL) are up 20% after Shanghai Fosun Pharmaceutical disclosed this morning a 5.19% stake in the company. Investors interpreting the investment as strategic, setting up an eventual takeover of Impax, is inaccurate, Wilbur tells investors in a research note. The analyst points out that Shanghai Fosun has a New York-based investment arm with positions in companies including Valeant Pharmaceuticals (VRX), Dova Pharmaceuticals (DOVA) and Nature's Sunshine Products (NATR). The stake is just a passive investment made because the investment arm of Shanghai Fosun believes in the Impax turnaround story "and nothing more," Wilbur contends. He keeps a Market Perform rating on Impax. The stock in afternoon trading is up 20%, or $3.62, to $21.58.
09/26/17
LEER
09/26/17
UPGRADE
LEER
Outperform
Dova Pharmaceuticals upgraded to Outperform from Market Perform at Leerink
07/24/17
LEER
07/24/17
INITIATION
Target $24
LEER
Market Perform
Dova Pharmaceuticals initiated with a Market Perform at Leerink
Leerink analyst Geoffrey Porges started Dova Pharmaceuticals with a Market Perform rating and a $24 price target based on his revenue forecast for its thrombopoietin receptor agonist avatrombopag in its first indication, pre-procedure bleeding prophylaxis in chronic liver disease patients with thrombocytopenia.
09/26/17
09/26/17
UPGRADE
Target $32

Outperform
Dova Pharmaceuticals upgraded to Outperform at Leerink
As previously reported, Leerink analyst Geoffrey Porges upgraded Dova Pharmaceuticals to Outperform from Market Perform after Shionogi announced results from its phase III trial investigating thrombopoietin receptor agonist lusutrombopag for the treatment of thrombocytopenia in patients with chronic liver disease undergoing an invasive procedure. The analyst notes that lusutrombopag is from the same class of drugs as Dova's avatrombopag, but is less effective ex-Japan, and believes Dova's avatrombopag has advantage. Porges also raised his price target on Dova's shares to $32 from $24.
EARS Auris Medical
$0.73

-0.0004 (-0.05%)

04/13/17
ROTH
04/13/17
INITIATION
Target $4.5
ROTH
Buy
Auris Medical initiated with a Buy at Roth Capital
Roth Capital analyst Sa'ar Yaniv started Auris Medical with a Buy rating and a $4.50 price target, saying the company has multiple late stage "shots-on-goal" in the coming 12-18 months.
04/13/17
04/13/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Auris Medical (EARS) initiated with a Buy at Roth Capital. 2. NCR Corp. (NCR) initiated with a Buy at Benchmark. 3. Guaranty Bancorp (GBNK) initiated with an Overweight at Piper Jaffray. 4. Six Flags (SIX) and SeaWorld (SEAS) were initiated with a Buy at SunTrust, while Cedar Fair (FUN) was initiated with a Hold. 5. Stericycle (SRCL) initiated with an Overweight at Barclays. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
ACHN Achillion
$4.37

0.3 (7.37%)

08/10/17
MAXM
08/10/17
NO CHANGE
Target $7
MAXM
Buy
Achillion price target raised to $7 from $5 at Maxim
Maxim analyst Jason Kolbert is introducing estimates for paroxysmal nocturnal hemoglobinuria in his model for Achillion after the company reported "proof of concept" news for its Factor D program. Adding in the potential for an eventual PHH indication leads him to raise his price target on Achillion shares to $7 from $5. He keeps a Buy rating on the stock.
08/10/17
08/10/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Unilever (UN, UL) downgraded to Underperform from Sector Perform at RBC Capital with analyst James Edwardes Jones citing valuation and his belief that the company may not meet its 2020 targets. 2. Masonite (DOOR) downgraded to Equal Weight from Overweight at Stephens. 3. Synacor (SYNC) downgraded to Hold from Buy at Craig-Hallum with analyst Jason Kreyer saying he is "unequivocally" disappointed that the AT&T (T)portal launch has not yet monetized at a rate anticipated. 4. NetEase (NTES) downgraded to Underperform from Outperform at CLSA. 5. Achillion (ACHN) downgraded to Neutral from Outperform at Baird with analyst Brian Skorney saying the PNH data reported earlier this week was better than expected but he is not convinced that given the drug's therapeutic window, dosing, and impact on LDH that it can be competitive with Soliris. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/11/17
LEER
08/11/17
NO CHANGE
Target $8
LEER
Outperform
Leerink talk with opinion leader suggests Achillion selloff overdone
Leerink analyst Joseph Schwartz says his talk with a key opinion leader who has extensive experience in paroxysmal nocturnal hemoglobinuria clinical development and patient care suggests the recent selloff in shares of Achillion Pharmaceuticals is overdone. The feedback indicates that investors are overemphasizing lactate dehydrogenase data without assigning much credit to the promise that other parameters, such as hemoglobin, fatigue score, and PNH clone size, seem to suggest, Schwartz tells investors in a research note. He reiterates an Overweight rating on shares of Achillion.
08/10/17
BARD
08/10/17
DOWNGRADE
Target $5
BARD
Neutral
Achillion downgraded to Neutral at Baird
As reported previously, Baird analyst Brian Skorney downgraded Achillion to Neutral from Outperform. He said the PNH data reported earlier this week was better than expected but he is not convinced that given the drug's therapeutic window, dosing, and impact on LDH that it can be competitive with Soliris. Skorney maintained his $5 price target on Achillion shares.
CDTX Cidara Therapeutics
$7.95

-0.1 (-1.24%)

05/25/17
LEER
05/25/17
NO CHANGE
Target $16
LEER
Outperform
Cidara selloff creates favorable risk/reward in Q4 data, says Leerink
Leerink analyst Paul Matteis believes the selloff in shares of Cidara Therapeutics since the company discontinued its CD101 topical program in February creates a favorable risk/reward profile. Read-through to the CD101 IV program, with Phase 2 data coming in Q4, is an error, Matteis tells investors in a research note. Pharmacokinetic, preclinical, safety and historical echinocandin data point to a "solid odds of success" for the IV program, the analyst contends. He raised his CD101 IV odds of success to 60% from 50% and his price target for the shares to $16 from $13. Matteis reiterates an Outperform rating on Cidara.
07/28/17
WBBS
07/28/17
DOWNGRADE
WBBS
Cidara Therapeutics downgraded to Sell from Hold at WBB Securities
08/11/17
WBBS
08/11/17
UPGRADE
WBBS
Hold
Cidara Therapeutics upgraded to Hold from Sell at WBB Securities
04/26/17
BTIG
04/26/17
NO CHANGE
Target $20
BTIG
Buy
Cidara Therapeutics price target raised to $20 from $15 at BTIG
BTIG analyst Timothy Chiang raised his price target on Cidara Therapeutics to $20 from $15, as he believes Cidara's once-weekly dosed broad spectrum antifungal agent could become a best-in-class product in the prophylaxis market. Chiang keeps a Buy rating on Cidara shares.
VRTX Vertex
$149.07

0.61 (0.41%)

09/14/17
RBCM
09/14/17
INITIATION
Target $175
RBCM
Outperform
Vertex initiated with an Outperform at RBC Capital
RBC Capital analyst Brian Abrahams started Vertex Pharmaceuticals with an Outperform rating and $175 price target. The analyst is bullish on the company's cystic fibrosis triple combo and its long-term competitive positioning.
07/27/17
OPCO
07/27/17
NO CHANGE
Target $175
OPCO
Outperform
Vertex price target raised to $175 from $150 at Oppenheimer
Oppenheimer analyst Hartaj Singh raised his price target for Vertex to $175 from $150 following Q2 results and business update to investors. The analyst continues to be bullish on Vertex and would urge investors that any potential sustained weakness should be a buying opportunity. Singh reiterates an Outperform rating on the shares.
09/07/17
LEER
09/07/17
NO CHANGE
LEER
Alexion, Celgene top picks at Leerink
Leerink analyst Geoffrey Porges notes large cap biotech stocks have performed strongly this year and have reversed some of the wide discount they were carrying compared to their history and to other medical products sectors. Further, he points out consensus revenue and earnings estimates for biotech companies have started to trend positively, after negative revisions earlier in the year. Porges still sees significant upside for many of the names in his coverage, and he anticipates that further appreciation can occur on the basis of recovering sentiment and multiples, further estimate revisions toward his current models, and confirmation of option value for unpriced pipeline opportunities. The analyst top picks are now Alexion (ALXN), Celgene (CELG), Regeneron (REGN), and Vertex (VRTX). Among his Market Perform rated stocks, his preference would be for AbbVie (ABBV).
09/26/17
LEER
09/26/17
NO CHANGE
Target $187
LEER
Outperform
ProQR Therapeutics QR-010 unlikely to challenge Vertex's medicines, says Leerink
Leerink analyst Geoffrey Porges notes that ProQR (PRQR) announced top line results from QR-010, an inhaled RNA oligonucleotide being studied as a disease modifying treatment in cystic fibrosis. The analyst says these results are confusing to interpret, but reinforce the high bar that Vertex (VRTX) has established with its recent cystic fibrosis breakthroughs. Porges believes QR-010 is unlikely to challenge Vertex's Medicines, and sees potential combination use. The analyst reiterates an Outperform rating and $187 price target on Vertex's shares.
BOLD Audentes Therapeutics
$29.97

0.5 (1.70%)

05/01/17
LEER
05/01/17
INITIATION
Target $22
LEER
Outperform
Audentes Therapeutics initiated with an Outperform at Leerink
Leerink analyst Joseph Schwartz started Audentes Therapeutics with an Outperform rating and $22 price target as he believes catalysts over the next 12 months have the potential to generate enthusiasm for the company's approach, which appears de-risked by strong preclinical animal model data.
10/10/16
PIPR
10/10/16
NO CHANGE
Target $24
PIPR
Overweight
AveXis data bodes well for Audentes gene therapy program, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer said additional data presented by AveXis (AVXS) from its ongoing Phase 1/2 trial in infantile-onset spinal muscular atrophy "augurs well" for Audentes Therapeutics' (BOLD) gene therapy program for X-linked myotubular myopathy, as he sees several points of similarity that provide a positive read-through though the companies are targeting different diseases. Schimmer, who does not have a rating on AveXis, reiterates his Overweight rating and $24 price target on Audentes shares.
08/16/17
EVER
08/16/17
INITIATION
Target $23
EVER
Outperform
Audentes Therapeutics initiated with an Outperform at Evercore ISI
Evercore ISI analyst Josh Schimmer initiated Audentes Therapeutics with an Outperform and a $23 price target.
WVE Wave Life Sciences
$23.25

1.5 (6.90%)

08/04/17
JMPS
08/04/17
NO CHANGE
JMPS
Wave Life Sciences added to best ideas list at JMP Securities
JMP Securities analyst Michael King says that investors should buy Wave Life ahead of its upcoming milestones, expected to occur before the end of the year. The analyst says that the company's technology is "impressive," and he added the stock to his best ideas list.
EDGE Edge Therapeutics
$10.61

0.76 (7.72%)

PRQR ProQR Therapeutics
$5.15

-0.05 (-0.96%)

09/28/16
JANY
09/28/16
INITIATION
JANY
Neutral
ProQR Therapeutics initiated with a Neutral at Janney Capital
Janney Capital analyst Roy Buchanan initiated ProQR Therapeutics with a Neutral rating saying there is too much uncertainty ahead of important phase 2 data for its oligonucleotide candidate QR-010 in undefinedF508 cystic fibrosis in mid-October
09/26/17
JMPS
09/26/17
NO CHANGE
Target $20
JMPS
Outperform
ProQR Therapeutics price target raised to $20 from $14 at JMP Securities
JMP Securities analyst Liisa Bayko called ProQR Therapeutics' efficacy data for its potential new CF medicine "encouraging" and increased her assumption for the success of eventual approval of the drug to 20% from 5%. Given the raised odds seen for success, she raised her price target on ProQR to $20 from $14 and keeps an Outperform rating on the shares.
CBAY CymaBay
$8.03

0.33 (4.29%)

09/19/17
CANT
09/19/17
INITIATION
CANT
Overweight
CymaBay initiated with an Overweight at Cantor
Cantor Fitzgerald analyst William Tanner started CymaBay Therapeutics with an Overweight rating and $16 price target. The analyst believes the company's seladelpar could become an important new therapy for primary biliary cholangitis and a possible treatment for non-alcoholic steatohepatitis.
09/14/17
OPCO
09/14/17
NO CHANGE
Target $15
OPCO
Outperform
Intercept Ocaliva dynamics highlight PBC opportunity, says Oppenheimer
Oppenheimer analyst Jay Olson says the Dear Doctor letter for Intercept's (ICPT) Ocaliva raises awareness of unmet medical need for patients with primary biliary cholangitis, or PBC. Since patients with Child-Pugh B/C cirrhosis were not studied in Ocaliva trials, the analyst believes the FDA's collaboration with Intercept to leverage PK modeling for dosing guidance which is included in the label and emphasized in the Dear Doctor letter highlights the importance of providing novel treatments to PBC patients. Olson expects these events to have a positive impact on the treatment of all PBC patients, and says CymaBay (CBAY) may benefit from these dynamics. He reiterates an Outperform rating and $15 price target on CymaBay's shares.
08/23/17
LEER
08/23/17
INITIATION
Target $12
LEER
Outperform
CymaBay initiated with an Outperform at Leerink
Leerink analyst Joseph Schwartz started CymaBay with an Outperform rating and $12 price target, noting that the company is currently developing seladelpar for the lead indication of primary biliary cholangitis, an autoimmune disease that causes progressive destruction of the bile ducts in the liver.
QURE uniQure
$8.78

-0.02 (-0.23%)

12/05/16
LEER
12/05/16
NO CHANGE
Target $9
LEER
Outperform
uniQure price target lowered to $9 from $23 at Leerink
Leerink analyst Joseph Schwartz assumed coverage of uniQure with an Outperform rating and lowered the price target on the shares to $9 from $23. The analyst believes the company's leadership and expertise in gene therapy should be a positive over the long-term, but resolutions to a number of uncertainties, questions, and optimizations remain essential in the near-term to enthuse investors.
11/28/16
JANY
11/28/16
NO CHANGE
Target $12
JANY
Buy
uniQure price target lowered to $12 from $18 at Janney Capital
Janney Capital analyst Debjit Chattopadhyay acknowledged he has "been wrong on" uniQure so far and cut his fair value estimate on the stock to $12 from $18, adding that the upcoming Hemophilia B update at the ASH meeting "may not be [a] big enough catalyst for the stock." However, he keeps a Buy rating on uniQure shares, as he believes the bottom "could be probably close at hand" and the company's cash balance is sufficient to fund operations into 2019 while its major programs are still intact.
11/22/16
JEFF
11/22/16
DOWNGRADE
Target $8
JEFF
Hold
uniQure downgraded to Hold from Buy at Jefferies
Jefferies analyst Eun Yang downgraded uniQure to Hold citing execution risks and a lack of near-term catalysts. uniQure's strategic review and prioritization announced last week "comes up short" in providing confidence in the company's strategy and execution, Yang tells investors in a research note. She cut her price target for the shares to $8 from $28.
06/29/17
OPCO
06/29/17
NO CHANGE
Target $17
OPCO
Outperform
Oppenheimer doctor survey supports bullish view on uniQure
Oppenheimer analyst Hartaj Singh says his firm's recent survey of 25 hematologists and oncologists supports his "continued bullish view" on uniQure. The survey suggests physician dissatisfaction with current treatments and a positive response to uniQure's blinded AMT-060 product profile, Singh tells investors in a research note. The analyst sees potential for 60% market penetration in three years after approval. He keeps an Outperform rating on uniQure with a $17 price target.
SCMP Sucampo
$11.70

-0.05 (-0.43%)

08/21/17
LEER
08/21/17
INITIATION
Target $15
LEER
Outperform
Sucampo reinitiated with an Outperform at Leerink
Leerink analyst Joseph Schwartz reinitiated Sucampo with an Outperform rating and a $15 price target saying it offers a "strong" management team which has brought strategic focus to the pipeline and business development efforts, cash flow generation, and a platform for a biotech pipeline focused on rare disease development opportunities.
04/04/17
LEER
04/04/17
NO CHANGE
Target $10.65
LEER
Market Perform
Vtesse acquisition strengthens Sucampo late-stage pipeline, says Leerink
Leerink analyst Jason Gerberry notes that Sucampo acquired Vtesse for $200M and in the process bolstered its late-stage pipeline by adding pivotal-stage VTS-270 for treatment of Niemann Pick Disease Type C. The analyst says Sucampo appears to have paid a fair price for the asset, which could deliver meaningful upside if Phase 3 data are positive in 1H18. He reiterates a Market Perform rating and $10.65 price target on the shares.
12/22/16
12/22/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Micron (MU) was upgraded to Buy from Hold at Cross Research, to Buy from Underperform at Needham, and to Buy from Hold at Summit Redstone. 2. Sunoco (SUN) upgraded to Outperform from Market Perform at FBR Capital with analyst Robert Balsamo saying the credit facility amendments announced reduce the need for a distribution cut. The analyst has a $32 price target for the shares. 3. National Instruments (NATI) upgraded to Outperform from Neutral at Baird with analyst Richard Eastman saying he sees the potential for accelerating revenue growth over the next few years combined with more determined focus to deliver operating leverage. 4. Merus (MRUS) upgraded to Buy from Neutral at Citi with analyst Yigal Nochomovitz saying the Incyte (INCY) collaboration deal has "very favorable" terms. 5. Sucampo (SCMP) upgraded to Buy from Neutral at Mizuho with the firm citing the sell-off in shares post the $260M convertible raise. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/22/16
MZHO
12/22/16
UPGRADE
MZHO
Buy
Sucampo upgraded to Buy from Neutral at Mizuho
Mizuho upgraded Sucampo to Buy with a $16 price target citing the sell-off in shares post the $260M convertible raise.

TODAY'S FREE FLY STORIES

JPM

JPMorgan

$97.99

0.37 (0.38%)

18:12
10/18/17
10/18
18:12
10/18/17
18:12
Hot Stocks
SEC names JPMorgan exec Redfearn Director of Division of Trading and Markets »

The Securities and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 20

    Oct

  • 22

    Oct

  • 23

    Oct

  • 02

    Nov

  • 05

    Nov

  • 27

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

VZ

Verizon

$48.65

0.25 (0.52%)

18:10
10/18/17
10/18
18:10
10/18/17
18:10
Periodicals
Verizon targets spring start of delayed online TV service, Bloomberg says »

Verizon web TV…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 01

    Nov

STLD

Steel Dynamics

$36.44

0.27 (0.75%)

18:04
10/18/17
10/18
18:04
10/18/17
18:04
Hot Stocks
Steel Dynamics CEO optimistic conditions in place to benefit FY18 consumption »

CEO Mark Millet said:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

CE

Celanese

$104.03

-0.24 (-0.23%)

18:03
10/18/17
10/18
18:03
10/18/17
18:03
Earnings
Celanese increases price for acetyls and engineered materials products »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STLD

Steel Dynamics

$36.44

0.27 (0.75%)

18:01
10/18/17
10/18
18:01
10/18/17
18:01
Earnings
Steel Dynamics reports Q3 ex-items EPS 66c, consensus 66c »

Reports Q3 revenue $2.4B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

OPTT

Ocean Power

$2.00

0.56 (38.89%)

17:59
10/18/17
10/18
17:59
10/18/17
17:59
Syndicate
Ocean Power files to sell common stock in 'best efforts' offering »

No amount was provided.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

TOSBF

Toshiba, also use TOSYY

$3.02

-0.03 (-0.98%)

, TOSYY

Toshiba, also use TOSBF

$18.20

-0.11 (-0.60%)

17:58
10/18/17
10/18
17:58
10/18/17
17:58
Periodicals
Japan regulators probing Toshiba reporting practices for FY16/17, Nikkei says »

Japan's Securities…

TOSBF

Toshiba, also use TOSYY

$3.02

-0.03 (-0.98%)

TOSYY

Toshiba, also use TOSBF

$18.20

-0.11 (-0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PNW

Pinnacle West

$87.34

-0.42 (-0.48%)

17:53
10/18/17
10/18
17:53
10/18/17
17:53
Hot Stocks
Pinnacle West raises quarterly divided 6.1% to 69.5c per share »

Pinnacle West…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Nov

  • 05

    Nov

  • 05

    Nov

  • 05

    Nov

GILD

Gilead

$80.01

-0.23 (-0.29%)

17:46
10/18/17
10/18
17:46
10/18/17
17:46
Hot Stocks
FDA grants regulatory approval to Kite's Yescarta »

Kite, a Gilead company,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 26

    Oct

  • 06

    Nov

  • 12

    Feb

POT

Potash

$19.24

0.08 (0.42%)

, AGU

Agrium

$107.73

0.55 (0.51%)

17:37
10/18/17
10/18
17:37
10/18/17
17:37
Hot Stocks
Potash, Agrium: India approves proposed merger of equals transaction »

Potash Corporation of…

POT

Potash

$19.24

0.08 (0.42%)

AGU

Agrium

$107.73

0.55 (0.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VMI

Valmont

$160.85

1.9 (1.20%)

17:36
10/18/17
10/18
17:36
10/18/17
17:36
Earnings
Valmont lowers FY17 adjusted EPS view to $6.90-$7.04 from $7.06, consensus $7.09 »

Annual guidance was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

NVO

Novo Nordisk

$50.13

0.82 (1.66%)

17:36
10/18/17
10/18
17:36
10/18/17
17:36
Hot Stocks
Novo Nordisk receives positive 16-0 vote from FDA Advisory Committe »

Novo Nordisk announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

CHFS

CHF Solutions

$8.30

-0.69 (-7.68%)

17:35
10/18/17
10/18
17:35
10/18/17
17:35
Syndicate
Breaking Syndicate news story on CHF Solutions »

CHF Solutions files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

VTGN

VistaGen Therapeutics

$1.31

0.04 (3.15%)

17:33
10/18/17
10/18
17:33
10/18/17
17:33
Syndicate
Breaking Syndicate news story on VistaGen Therapeutics »

VistaGen Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLNW

Limelight Networks

$4.48

0.12 (2.75%)

, URI

United Rentals

$144.32

0.98 (0.68%)

17:32
10/18/17
10/18
17:32
10/18/17
17:32
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

LLNW

Limelight Networks

$4.48

0.12 (2.75%)

URI

United Rentals

$144.32

0.98 (0.68%)

KMI

Kinder Morgan

$18.58

-0.1 (-0.54%)

ADBE

Adobe

$153.00

2.62 (1.74%)

CNAT

Conatus

$5.15

0.05 (0.98%)

EBAY

eBay

$37.97

0.48 (1.28%)

HXL

Hexcel

$58.94

0.39 (0.67%)

CCI

Crown Castle

$100.96

-0.42 (-0.41%)

ESTE

Earthstone Energy

$10.54

-0.15 (-1.40%)

PEGI

Pattern Energy

RXDX

Ignyta

$16.25

1.9 (13.24%)

HCA

HCA Healthcare

$77.45

0.63 (0.82%)

KLAC

KLA-Tencor

$108.09

0.08 (0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 19

    Oct

  • 22

    Oct

  • 26

    Oct

  • 06

    Nov

  • 06

    Nov

  • 14

    Nov

  • 15

    Nov

  • 15

    May

  • 16

    May

  • 19

    Oct

  • 19

    Oct

  • 20

    Oct

VMI

Valmont

$160.85

1.9 (1.20%)

17:31
10/18/17
10/18
17:31
10/18/17
17:31
Earnings
Valmont reports Q3 adjusted EPS $1.56, consensus $1.61 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

AGEN

Agenus

$4.71

0.04 (0.86%)

17:31
10/18/17
10/18
17:31
10/18/17
17:31
Syndicate
Breaking Syndicate news story on Agenus »

Agenus files $250M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

PEGI

Pattern Energy

17:31
10/18/17
10/18
17:31
10/18/17
17:31
Hot Stocks
Pattern Energy sees Q3 operating loss greater than Q316 »

On October 18, Pattern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

GE

General Electric

$23.12

-0.07 (-0.30%)

17:25
10/18/17
10/18
17:25
10/18/17
17:25
Periodicals
General Electric CEO cutting expenses, employees, WSJ reports »

General Electric's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

UNB

Union Bankshares

$47.10

-0.8 (-1.67%)

17:20
10/18/17
10/18
17:20
10/18/17
17:20
Hot Stocks
Union Bankshares sees Q418 charge of $3.2M on plan termination »

On October 18, the board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OIS

Oil States

$23.75

-0.2 (-0.84%)

17:19
10/18/17
10/18
17:19
10/18/17
17:19
Earnings
Oil States lowers Q3 revenue view to $164M from $165M-$185M, consensus $177.77M »

Oil States anticipates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

AXP

American Express

$92.08

0.39 (0.43%)

17:18
10/18/17
10/18
17:18
10/18/17
17:18
Hot Stocks
American Express says on track to cut $1B in costs by end of the year »

Says on track to cut $1B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 22

    Oct

  • 08

    Nov

OIS

Oil States

$23.75

-0.2 (-0.84%)

17:16
10/18/17
10/18
17:16
10/18/17
17:16
Hot Stocks
Breaking Hot Stocks news story on Oil States »

Oil States lowers Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

AXP

American Express

$92.08

0.39 (0.43%)

17:08
10/18/17
10/18
17:08
10/18/17
17:08
Hot Stocks
American Express says 'right time' for leadership transition »

Comments taken from Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 22

    Oct

  • 08

    Nov

APRN

Blue Apron

$5.30

-0.08 (-1.49%)

17:06
10/18/17
10/18
17:06
10/18/17
17:06
Hot Stocks
Blue Apron to cut roughly 6% of total workforce, inclur roughly $3.5M in expense »

Blue Apron said in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.